

Table 6. SGX393-dasatinib combination mutagenesis study

SGX393 + dasatinib combinations		Total wells (sequenced clones)	Mutation recovered	Number of occurrences	Frequency (%)	Mutations recovered (by residue)	Frequency (by residue) (%)
[SGX393]	[dasatinib]						
240nM	5nM	96 (n=7)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			G250E	2	28.6	250	28.6
			E255V	1	14.3	255	14.3
			F317V	4	57.1	317	57.1
240nM	25nM	96 (n=5)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			F317V	5	100.0	317	100.0
240nM	100nM	96 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
240nM	200nM	96 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
480nM	5nM	288 (n=25)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	2	8.0	248	8.0
			G250E	4	16.0	250	16.0
			Q252H	1	4.0	252	4.0
			E255V	1	4.0	255	4.0
			F317I	1	4.0		
			F317L	4	16.0	317	68.0
			F317V	12	48.0		
480nM	25nM	288 (n=8)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			F317I	1	12.5	317	100.0
			F317V	7	87.5		
480nM	100nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
480nM	200nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
960nM	5nM	288 (n=16)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			G250E	1	6.3	250	6.3
			E255V	1	6.3	255	6.3
			F317C	1	6.3		
			F317L	1	6.3	317	87.5
			F317V	12	75.0		
960nM	25nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
960nM	100nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
960nM	200nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	5nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	25nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	100nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	200nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0